США - англійська - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr), isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - rifampin 300 mg - in the treatment of tuberculosis, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. bacteriologic smears or cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and isoniazid, and they should be repeated throughout therapy to monitor response to the treatment. if test results show resistance to any of the components of rifamate and the patient is not responding to therapy, the drug regimen should be modified. rifamate is indicated for pulmonary tuberculosis in which organisms are susceptible, and when the patient has been titrated on the individual components and it has therefore been established that this fixed dosage is therapeutically effective. this fixed-dosage combination drug is not recommended for initial ther

США - англійська - NLM (National Library of Medicine)

trigen laboratories, inc. - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), niacinamide (unii: 25x51i8rd4) (niacinamide - - folic acid 1 mg - vol-care rx is indicated for the supplemental requirements of patients with nutritional deficiencies or are in need of nutritional supplementation. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hydrochloride tablets are indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most freguently used regimens have been the following: -  ethambutol hydrochloride tablets plus isoniazid -  ethambutol hydrochloride tablets plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hydrochloride tablets should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has

США - англійська - NLM (National Library of Medicine)

cardinal health - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg

США - англійська - NLM (National Library of Medicine)

carilion materials management - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 100 mg - ethambutol hydrochloride is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: - ethambutol plus isoniazid - ethambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - - myambutol plus isoniazid - myambutol plus isoniazid plus streptomycin. myambutol is contraindicated in patients who are known to be hypersensitive to this drug. it is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. myambutol is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

США - англійська - NLM (National Library of Medicine)

virtus pharmaceuticals - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate (unii: 9e8x80d2l0) (.alpha.-tocopherol - unii:h4n855pnz1), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), biotin (unii: - ascorbic acid 25 mg - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

США - англійська - NLM (National Library of Medicine)

virtus pharmaceuticals llc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 25 mg

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - myambutol is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: myambutol plus isoniazid myambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, myambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used with myambutol have incl

США - англійська - NLM (National Library of Medicine)

department of state health services, pharmacy branch - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hci is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: - ethambutol hci plus isoniazid - ethambutol hci plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used w